AU2004210753A1 - Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent - Google Patents

Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent Download PDF

Info

Publication number
AU2004210753A1
AU2004210753A1 AU2004210753A AU2004210753A AU2004210753A1 AU 2004210753 A1 AU2004210753 A1 AU 2004210753A1 AU 2004210753 A AU2004210753 A AU 2004210753A AU 2004210753 A AU2004210753 A AU 2004210753A AU 2004210753 A1 AU2004210753 A1 AU 2004210753A1
Authority
AU
Australia
Prior art keywords
amido
formula
products
methylquinolinio
pyridinedicarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004210753A
Other languages
English (en)
Inventor
Chafke Belmokhtar
Herve Bouchard
Thomas Caulfield
Dennis Gomez
Lionel Guittat
Augustin Hittinger
Patrick Mailliet
Eliane Mandine
Jean-Louis Mergny
Jean-Francois Riou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Aventis Pharma SA
Institute Curie
National Museum of Natural History
Université de Reims Champagne-Ardenne
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Centre National de la Recherche Scientifique
Commissariat a lEnergie Atomique CEA
Aventis Pharma SA
Institute Curie
National Museum of Natural History
Université de Reims Champagne-Ardenne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Commissariat a lEnergie Atomique CEA, Aventis Pharma SA, Institute Curie, National Museum of Natural History, Université de Reims Champagne-Ardenne filed Critical Centre National de la Recherche Scientifique
Publication of AU2004210753A1 publication Critical patent/AU2004210753A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004210753A 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent Abandoned AU2004210753A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
FR03/01478 2003-02-07
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Publications (1)

Publication Number Publication Date
AU2004210753A1 true AU2004210753A1 (en) 2004-08-26

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004210753A Abandoned AU2004210753A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent

Country Status (8)

Country Link
EP (1) EP1603898A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518726A (cg-RX-API-DMAC7.html)
AU (1) AU2004210753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407320A (cg-RX-API-DMAC7.html)
CA (1) CA2514105A1 (cg-RX-API-DMAC7.html)
FR (1) FR2850970B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05007648A (cg-RX-API-DMAC7.html)
WO (1) WO2004072027A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
EP2061464A2 (en) * 2006-09-14 2009-05-27 Ramot, at Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
JP4410844B1 (ja) 2008-05-27 2010-02-03 パナソニック株式会社 G−quadruplex検出方法、G−quadruplex形成DNA検出方法およびテロメラーゼ活性測定方法
JP4510929B1 (ja) 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (zh) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
FR2819255B1 (fr) * 2001-01-09 2003-02-28 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent

Also Published As

Publication number Publication date
BRPI0407320A (pt) 2006-02-21
FR2850970B1 (fr) 2006-07-07
EP1603898A2 (fr) 2005-12-14
MXPA05007648A (es) 2006-12-15
WO2004072027A3 (fr) 2004-09-23
WO2004072027A2 (fr) 2004-08-26
JP2006518726A (ja) 2006-08-17
CA2514105A1 (fr) 2004-08-26
FR2850970A1 (fr) 2004-08-13

Similar Documents

Publication Publication Date Title
Eissa et al. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors
US6995175B2 (en) Chemical derivatives and their application as antitelomerase agent
US20090226411A1 (en) Chemical derivatives and their application as antitelomerase agents
Liao et al. 12-N-Methylated 5, 6-dihydrobenzo [c] acridine derivatives: A new class of highly selective ligands for c-myc G-quadruplex DNA
JP2003515604A (ja) アリールアミン誘導体およびそれらの抗−テロメラーゼ剤としての使用
CA2729745A1 (en) Oxindole compounds
EP2523938A1 (en) Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
EP2881397B1 (en) Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
AU2016228634A1 (en) Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
US20230219895A1 (en) Oxynitidine derivatives useful as inhibitors of topoisomerase ib (top1) and tyrosyl-dna phosphodiesterase 1 (tdp1)
JP2006518726A (ja) G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用
AU2002251140B2 (en) Chemical derivatives and their use as anti-telomerase agent
US20070232572A1 (en) Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
US7179816B2 (en) Chemical derivatives and their application as antitelomerase agents
Wu et al. Disubstituted 2-phenyl-benzopyranopyrimidine derivatives as a new type of highly selective ligands for telomeric G-quadruplex DNA
CN111072640A (zh) 喹唑啉类衍生物及其制备方法和应用
EP3632912B1 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
US11065251B2 (en) PAK1 inhibitors and uses thereof
AU2002229859B2 (en) Chemical derivatives and their use as anti-telomerase agent
WO2008126123A2 (en) Water-soluble coronene derivatives active as inhibitors of telomerase
CN109400626B (zh) 一种双-氟喹诺酮噁二唑脲类氟罗沙星衍生物及其制备方法和应用
WO2026105155A1 (en) Tricyclic compound for breast and ovarian cancer treatment
CN119431354A (zh) 苯并五元杂环类衍生物及其应用
Hanh et al. Development of G-quadruplex stabilizing compounds identified through a High-Throughput Screen
WO2020023700A2 (en) OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (Tdp1)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application